Incyte Corporation (INCY)

NASDAQ: INCY · IEX Real-Time Price · USD
53.01
-0.21 (-0.39%)
Apr 17, 2024, 3:41 PM EDT - Market open
-0.39%
Market Cap 11.90B
Revenue (ttm) 3.70B
Net Income (ttm) 597.60M
Shares Out 224.53M
EPS (ttm) 2.65
PE Ratio 20.08
Forward PE 11.58
Dividend n/a
Ex-Dividend Date n/a
Volume 1,783,235
Open 53.22
Previous Close 53.22
Day's Range 52.81 - 53.80
52-Week Range 50.27 - 75.74
Beta 0.67
Analysts Buy
Price Target 75.31 (+42.07%)
Earnings Date Apr 30, 2024

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 4, 1993
Employees 2,524
Stock Exchange NASDAQ
Ticker Symbol INCY
Full Company Profile

Financial Performance

In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $75.31, which is an increase of 42.07% from the latest price.

Price Target
$75.31
(42.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Incyte to Report First Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202...

6 days ago - Business Wire

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)---- $INCY--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.

16 days ago - Business Wire

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that ...

16 days ago - GlobeNewsWire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

18 days ago - Business Wire

The Stock Market Is Already Way Up. 8 Stocks That Can Still Outperform.

Finding promising stocks is harder, given that the S&P 500 has risen by about one-third over 12 months.

Other symbols: AMTDRIPEPPGSBUXTYLV
5 weeks ago - Barrons

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.

5 weeks ago - Business Wire

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa.

5 weeks ago - Business Wire

New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

6 weeks ago - Business Wire

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative ne...

6 weeks ago - Business Wire

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...

6 weeks ago - GlobeNewsWire

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ax...

7 weeks ago - Business Wire

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference.

2 months ago - Business Wire

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities.

2 months ago - Business Wire

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®).

2 months ago - Business Wire

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2023 Financial Results.

3 months ago - Business Wire

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Other symbols: CIELVHUMPODDUNHXLVZTS
3 months ago - Market Watch

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference.

3 months ago - Business Wire

6 Stock Picks in Healthcare for 2024

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

Other symbols: BIOBMYCIHUMMRNA
4 months ago - Barrons

Incyte Stock Is the S&P 500's Top Performer. Here's Why It's Surging.

Shares of the biopharmaceutical company are on pace for their best day in more than six years.

4 months ago - Barrons

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Uns...

4 months ago - Business Wire

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)---- $INCY--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in C...

4 months ago - Business Wire

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting.

5 months ago - Business Wire

Drugmaker Incyte's quarterly profit beats on lower costs

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.

6 months ago - Reuters

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.

6 months ago - Business Wire

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023.

6 months ago - Business Wire